-- 黒竜江ZBD製薬（上海証券取引所：603567）の製品2点が、中国の伝統医薬品調達プログラムの入札で落札したことが、木曜日に上海証券取引所に提出された書類で明らかになった。 書類によると、落札された製品は、発熱や喉の痛みに効く小児用速効性糖液と、狭心症や胸痛に効く香丹注射液である。
Related Articles
Asia
China Shineway Pharmaceutical's Turnover Slides 18% in Q1
China Shineway Pharmaceutical Group (HKG:2877) recorded a turnover of 624 million yuan in the first quarter, down 18% year over year.The Hong Kong-listed pharmaceuticals company said Thursday turnover from its injection, TCM formula granules and other products fell during the period, while that for soft capsule and granule products increased.
$HKG:2877
International
Q1 US Nonfarm Productivity Rise More Than Expected, Unit Labor Costs Growth Slows
Nonfarm productivity rose by 0.8% in Q1 after a downwardly revised 1.6% increase in Q4, above expectations for a 0.6% gain in a survey compiled by Bloomberg as of 7:40 am ET, data released by the Bureau of Labor Statistics showed.Output growth accelerated to 1.5% from 1.3% in the previous quarter, but hours worked rebounded by 0.7% after a 0.2% decrease in the previous quarter.Unit labor costs rose by 2.3% gain after a 4.6% gain in Q4, below expectations for a 2.5% increase. A slowdown in compensation growth was larger than the deceleration in productivity growth, accounting for the slower pace of unit labor cost growth.
Research
Research Alert: Trgp: Strength In Q1 With Higher Volumes
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:TRGP posted Q1 2026 adjusted EBITDA of $1.40B vs. $1.18B in Q1 2025, beating consensus by 4.1%, led by record Permian natural gas volumes of 6.73 Bcf/d (+12%) and record NGL fractionation volumes of 1.145 mmb/d (+17%). Both G&P and L&T segments delivered strong results, with adjusted operating margins expanding 16% and 18% respectively, reflecting higher throughput volumes and improved optimization opportunities. The robust operational performance underscores TRGP's dominant Permian position and integrated asset base advantages. Management raised 2026 EBITDA guidance to $5.7B-$5.9B, with the $5.8B midpoint implying 17% growth over 2025 levels. TRGP has six new Permian processing plants in development for 2027-28, with 2026 growth capex expected around $4.5B. The Delaware Express NGL pipeline expansion began operations in May, enhancing Permian-Mont Belvieu connectivity. TRGP returned $55M to shareholders via buybacks and raised the dividend 25% to $5.00 annually, yielding 2.0%.
$TRGP